Neurobo Pharmaceuticals Stock Z Score
NRBO Stock | USD 3.02 0.10 3.21% |
Neurobo | Z Score |
Neurobo Pharmaceuticals Company Z Score Analysis
Neurobo Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Neurobo Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Neurobo Pharmaceuticals is extremely important. It helps to project a fair market value of Neurobo Stock properly, considering its historical fundamentals such as Z Score. Since Neurobo Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neurobo Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neurobo Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition |
Based on the company's disclosures, Neurobo Pharmaceuticals has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Neurobo Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurobo Pharmaceuticals' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurobo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Neurobo Pharmaceuticals by comparing valuation metrics of similar companies.Neurobo Pharmaceuticals is currently under evaluation in z score category among related companies.
Neurobo Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Neurobo Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Neurobo Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Neurobo Pharmaceuticals' value.Shares | Vanguard Group Inc | 2023-12-31 | 0.0 | Two Sigma Investments Llc | 2023-09-30 | 0.0 | Virtu Financial Llc | 2023-12-31 | 0.0 | Two Sigma Securities, Llc | 2023-12-31 | 0.0 | Citadel Advisors Llc | 2023-09-30 | 46.4 K | Hudson Bay Capital Management Lp | 2023-12-31 | 41.7 K | Geode Capital Management, Llc | 2023-12-31 | 17.3 K | Blackrock Inc | 2023-12-31 | 5.3 K | Tower Research Capital Llc | 2023-12-31 | 2.2 K | Wells Fargo & Co | 2023-12-31 | 25.0 | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 25.0 |
Neurobo Fundamentals
Return On Equity | -0.65 | ||||
Return On Asset | -0.35 | ||||
Current Valuation | (6.93 M) | ||||
Shares Outstanding | 4.91 M | ||||
Shares Owned By Insiders | 61.66 % | ||||
Shares Owned By Institutions | 1.36 % | ||||
Number Of Shares Shorted | 61.89 K | ||||
Price To Earning | (1.44) X | ||||
Price To Book | 1.06 X | ||||
Revenue | 7 K | ||||
EBITDA | (15.88 M) | ||||
Net Income | (12.47 M) | ||||
Cash And Equivalents | 8.85 M | ||||
Cash Per Share | 9.96 X | ||||
Total Debt | 203 K | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 8.07 X | ||||
Book Value Per Share | 3.40 X | ||||
Cash Flow From Operations | (10.8 M) | ||||
Short Ratio | 0.25 X | ||||
Earnings Per Share | (2.46) X | ||||
Target Price | 36.5 | ||||
Beta | -0.46 | ||||
Market Capitalization | 15.31 M | ||||
Total Asset | 22.78 M | ||||
Retained Earnings | (108.27 M) | ||||
Working Capital | 16.55 M | ||||
Current Asset | 21.62 M | ||||
Current Liabilities | 11.75 M | ||||
Net Asset | 22.78 M |
About Neurobo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurobo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Neurobo Pharmaceuticals Piotroski F Score and Neurobo Pharmaceuticals Valuation analysis. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.Note that the Neurobo Pharmaceuticals information on this page should be used as a complementary analysis to other Neurobo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Neurobo Stock analysis
When running Neurobo Pharmaceuticals' price analysis, check to measure Neurobo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurobo Pharmaceuticals is operating at the current time. Most of Neurobo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neurobo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurobo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neurobo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Directory Find actively traded commodities issued by global exchanges |
Is Neurobo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Return On Assets (0.35) | Return On Equity (0.65) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.